The World Health Organization (WHO) said on Monday it had "temporarily" suspended clinical trials of hydroxychloriquine as a potential treatment for COVID-19 as a precautionary measure, AFP reports.
The decision follows the publication last week of a study in the Lancet, which indicated that using the drug on COVID-19 patients could increase their likelihood of dying, WHO chief Tedros Adhanom Ghebreyesus told a virtual press conference.
Tedros said that the executive group of the so-called Solidarity Trial, in which hundreds of hospitals across several countries have enrolled patients to test several possible treatments for the novel coronavirus, had as a precaution suspended trials using that drug.
"The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board," Tedros said, according to AFP.
"The other arms of the trial are continuing," he stressed.
Hydroxychloroquine is normally used to treat arthritis but pronouncement from public figures including US President Donald Trump, who announced last week he is taking the drug, has prompted governments to bulk buy the medicine.
Brazil's health minister also recommended last week using hydroxychloroquine, as well as the anti-malarial chloroquine, to treat even mild COVID-19 cases.
The Lancet study found that both drugs can produce potentially serious side effects, particularly heart arrhythmia, as well as that neither drug benefitted patients hospitalized with COVID-19.
Tedros stressed Monday that the two drugs "are accepted as generally safe for use in patients with autoimmune diseases or malaria."
WHO chief scientist Soumya Swaminathan told the briefing that the WHO-backed Solidarity Trial had been looking only at the effects of hydroxychloroquine and not chloroquine.
The decision on suspending enrolment for trials using hydroxychloroquine was "a temporary measure", she said.